Drug Trial Radar · NCT04630028
A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Mar 17, 2021
Primary completion
May 8, 2025
Study completion Jun 5, 2025
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics \[PK\]) in pediatric participants with moderately to severely active UC.
Conditions
- Colitis, Ulcerative
Interventions
Ustekinumab Dose Based on BSA and Body WeightDrug
As per BSA and body weight Ustekinumab will be administered SC and IV.
Matching PlaceboDrug
Placebo will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Global: Percentage of Participants With Clinical Remission at Induction Week 8Time frame: Induction Week 8
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 up to Maintenance Week 44 (Study Week 52)
- Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
- Number of Participants With AEs Leading to Discontinuation of Study InterventionTime frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
- Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
- Number of Participants With Abnormalities in Clinical Laboratory Parameters: HematologyTime frame: Induction Period: From Induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
- Number of Participants With Abnormalities in Clinical Laboratory Parameters: ChemistryTime frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
- Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
- Serum Ustekinumab ConcentrationsTime frame: Induction Period: Week I-0, 1-hour pre and post infusion; Week I-2, I-4, and Week I-8; Maintenance Period: Week M-4, M-8, M-12, M-16, M-24, M-32, M-36, and M-44
Locations
58 sites in 9 countries. Site status is shown where the registry gives one.
Nemours DuPont Hospital for Children
Wilmington, Delaware
Children's Center for Digestive Health Care
Atlanta, Georgia
Mayo Clinic
Rochester, Minnesota
Morristown Memorial Hospital
Morristown, New Jersey
Levine Childrens at Atrium Health
Charlotte, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Penn State Hershey Children's Hospital
Hershey, Pennsylvania
Cook Childrens Medical Center
Fort Worth, Texas
Pediatric Specialists Of Virginia
Fairfax, Virginia
Universitair Kinderziekenhuis Koningin Fabiola
Brussels, Belgium
Cliniques Universitaires Saint Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
UZ Brussel
Jette, Belgium
UZ Leuven
Leuven, Belgium
Universitätsklinikum Aachen
Aachen, Germany
Charite-Universitätsmedizin Berlin - Berlin
Berlin, Germany
Universitatsklinikum Erlangen
Erlangen, Germany
Universitatsklinikum Essen
Essen, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Dr. von Haunersches Kinderspital
Munich, Germany
KUNO Klinik St. Hedwig
Regensburg, Germany
Universitatsklinikum Ulm
Ulm, Germany
Semmelweis Egyetem
Budapest, Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary
Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
Miskolc, Hungary
Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz
Nyíregyháza, Hungary
Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum
Szeged, Hungary
Shamir Medical Center Assaf Harofeh
Be’er Ya‘aqov, Israel
Rambam Medical Center
Haifa, Israel
Carmel Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Schneider Children's Medical Center
Petah Tikva, Israel
Sheba Medical Center
Ramat Gan, Israel
Juntendo University Hospital
Bunkyō City, Japan
Gunma University Hospital
Gunma, Japan
Kindai University Nara Hospital
Ikoma, Japan
Kurume University Hospital
Kurume, Japan
Saitama Childrens Medical Center
Saitama Shi, Japan
Miyagi Children's Hospital
Sendai, Japan
National Center for Child Health and Development
Setagaya Ku, Japan
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.